# Ocular Allergy Treatment Practical Impact Trial

> **NCT01808768** · PHASE4 · UNKNOWN · sponsor: **Starx Research Center, LLC** · enrollment: 50 (estimated)

## Conditions studied

- Allergic Conjunctivitis
- Rhinoconjunctivitis

## Interventions

- **DRUG:** Alcaftadine

## Key facts

- **NCT ID:** NCT01808768
- **Lead sponsor:** Starx Research Center, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2013-10
- **Final completion:** 2013-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808768, "Ocular Allergy Treatment Practical Impact Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01808768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*